-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-011 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-011 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-011 in Systemic Sclerosis (Scleroderma) Drug Details: FT-011 (SHP-627) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DM-199 in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-199 in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in IgA Nephropathy (Berger's Disease) Drug Details: DM-199...
-
Sector Analysis
Canada General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2027
Canada General Insurance Market Report Overview The gross written premium of the Canadian general insurance market was CAD77.6 billion ($59.6 billion) in 2022 and is expected to achieve a CAGR of more than 6% during 2023-2027. The Canada general insurance market research report provides in-depth market analysis, information, insights, and a detailed outlook by product category for the Canadian general insurance segment. It also provides values for key performance indicators such as gross written premium, penetration, and premium ceded and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FT-011
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FT-011 Drug Details FT-011 (SHP-627) is under development for the treatment of focal segmental...
-
Sector Analysis
Ireland Service Station Market Size, (Forecourt Sales by Fuel, Car Wash, Convenience and Foodservice), Fuel Retailer Profiles and Forecast, 2021-2026
The Ireland forecourt market size was valued at EUR4.99 billion ($4.89 billion) in 2021 and is expected to achieve a CAGR of more than 3% during 2022-2026. Forecourt sales posted healthy growth in 2018 before declining in 2019 and 2020 owing to the COVID-19 crisis. However, in 2021, fuel value made a strong recovery. Fuel will unsurprisingly continue to make up the largest share of revenue, but the fuel mix will become more diversified. The presence of electric vehicles (EVs)...
-
Product Insights
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Idiopathic Pulmonary Fibrosis (IPF) symptoms include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness, and weight loss. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents, and anticoagulants. The IPF pipeline drugs market research report provides an analysis of the IPF drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history...
-
Product Insights
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glomerulonephritis is a disease of the kidney, characterized by inflammation of the glomeruli. Some factors that increase the chances of getting glomerulonephritis include a family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure. The Glomerulonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers...
-
Product Insights
Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glaucoma signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision, and reddening of the eye. The Glaucoma pipeline drugs market research report provides an analysis of the Glaucoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...
-
Product Insights
Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant. Global Markets Direct’s report features investigational drugs from across globe. The Systemic Sclerosis (Scleroderma) - Drugs In Development research report provides a comprehensive overview on the therapeutics  under  development  for  Systemic  Sclerosis  (Scleroderma),  complete  ...